Endoscopic and Histological Mucosal Healing in Ulcerative Colitis in the First Year of Diagnosis: Results from a Population-based Inception Cohort from Six Countries in Asia
暂无分享,去创建一个
S. Ng | Justin C.Y. Wu | F. Chan | J. Sung | D. Ong | Q. Ouyang | J. Sung | J. Ching | Whitney Tang | J. Limsrivilai | M. Simadibrata | S. Aniwan | Jinwen Zhang | M. Kyaw | H. Yu | M. Abdullah | Yu-fang Wang | Gani Niamul | C. Leung | S. Ng
[1] P. Higgins,et al. Endoscopic Mucosal Healing Predicts Favorable Clinical Outcomes in Inflammatory Bowel Disease: A Meta-analysis , 2016, Inflammatory bowel diseases.
[2] S. Ng,et al. Early Course of Inflammatory Bowel Disease in a Population-Based Inception Cohort Study From 8 Countries in Asia and Australia. , 2016, Gastroenterology.
[3] S. Travis,et al. Development and validation of the Nancy histological index for UC , 2015, Gut.
[4] S. Ng,et al. Factors Associated with Mucosal Healing in Patients with Ulcerative Colitis in Clinical Remission , 2015, Inflammatory bowel diseases.
[5] S. Travis,et al. Systematic review: histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? An IOIBD initiative. , 2014, Journal of Crohn's & colitis.
[6] S. Brand,et al. Rate and Predictors of Mucosal Healing in Patients with Inflammatory Bowel Disease Treated with Anti-TNF-Alpha Antibodies , 2014, PloS one.
[7] L. Peyrin-Biroulet,et al. Histologic remission: the ultimate therapeutic goal in ulcerative colitis? , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[8] S. Ng,et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn's and colitis epidemiology study. , 2013, Gastroenterology.
[9] P. Rutgeerts,et al. Correlation Between the Endoscopic and Histologic Score in Assessing the Activity of Ulcerative Colitis , 2013, Inflammatory bowel diseases.
[10] B. Flourié,et al. Impact of mucosal healing on long‐term outcomes in ulcerative colitis treated with infliximab: a multicenter experience , 2013, Alimentary pharmacology & therapeutics.
[11] M. Osterman. Mucosal Healing in Inflammatory Bowel Disease , 2013, Journal of clinical gastroenterology.
[12] S. Robson,et al. Predictors of Endoscopic Inflammation in Patients With Ulcerative Colitis in Clinical Remission , 2013, Inflammatory bowel diseases.
[13] R. D'Incà,et al. Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: A prospective, multicenter study , 2012, Inflammatory bowel diseases.
[14] Subrata Ghosh,et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. , 2012, Gastroenterology.
[15] P. Hellström,et al. Clinical trial: colectomy after rescue therapy in ulcerative colitis – 3‐year follow‐up of the Swedish‐Danish controlled infliximab study , 2010, Alimentary pharmacology & therapeutics.
[16] L. Peyrin-Biroulet,et al. Clinical implications of mucosal healing for the management of IBD , 2010, Nature Reviews Gastroenterology &Hepatology.
[17] W. Sandborn,et al. An Update on the Epidemiology of Inflammatory Bowel Disease in Asia , 2008, The American Journal of Gastroenterology.
[18] N. Harpaz,et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. , 2007, Gastroenterology.
[19] M. Vatn,et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. , 2007, Gastroenterology.
[20] J. Satsangi,et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[21] P. Rutgeerts,et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. , 2004, Gastroenterology.
[22] S. Hanauer,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[23] A. Cohen,et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. , 2001, Gastroenterology.
[24] W. Tremaine,et al. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.